Research Topics
Genomes and Genes | Neal J MeropolSummaryAffiliation: Fox Chase Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Cancer patient preferences for quality and length of lifeNeal J Meropol
Division of Medical Science and Population Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Cancer 113:3459-66. 2008..The objective of the current study was to describe cancer patient values regarding QOL and LOL and explore associations with communication preferences...
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancerNeal J Meropol
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Clin Oncol 24:4069-77. 2006....
Barriers to clinical trial participation as perceived by oncologists and patientsNeal J Meropol
Divisions of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Natl Compr Canc Netw 5:655-64. 2007..We concluded that characterizing oncologist and patient perceived barriers can help improve communication and decision making about clinical trials, such that participation may be optimized...
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281)Neal J Meropol
Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
J Clin Oncol 26:3229-34. 2008....
Cost of cancer care: issues and implicationsNeal J Meropol
Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Clin Oncol 25:180-6. 2007..Our overall goal is to frame debate about health policy concerns that influence the clinical practice of oncology...
Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiationAndre Konski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 74:55-9. 2009....
Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinomaAndre A Konski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 69:358-63. 2007....
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinomaIgor A Astsaturov
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
Am J Clin Oncol 34:70-5. 2011..We evaluated the role of the anti-vascular endothelial growth factor antibody bevacizumab as second-line treatment for patients with metastatic pancreatic cancer...
Using health communication best practices to develop a web-based provider-patient communication aid: the CONNECT studyLinda Fleisher
Fox Chase Cancer Center, Philadelphia, PA 19012, United States
Patient Educ Couns 71:378-87. 2008..This paper highlights the development of a theory-guided, web-based communication aid (CONNECT), designed to facilitate treatment decision-making among patients with advanced cancer...
Barriers to participation in cancer prevention clinical trialsMichael J Hall
Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Acta Oncol 49:757-66. 2010..We sought to characterize barriers to prevention trial participation among medical oncologists and first-degree relatives of their patients...
A randomized trial of generic versus tailored interventions to increase colorectal cancer screening among intermediate risk siblingsSharon L Manne
Fox Chase Cancer Center, Philadelphia, PA, USA
Ann Behav Med 37:207-17. 2009..Tailored interventions may increase participation in appropriate colorectal cancer screening...
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumorsSteven J Cohen
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
Am J Clin Oncol 31:1-5. 2008..Thus, we performed this phase I study to document the safety and obtain preliminary efficacy data for the combination of capecitabine, oxaliplatin, and bortezomib...
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200Bruce J Giantonio
University of Pennsylvania, Philadelphia, PA, USA
J Clin Oncol 25:1539-44. 2007..This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer...
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinomaSteven J Cohen
Department of Medical Oncology, Fox Chase Cancer Center, Jeanes Hospital, Philadelphia, PA 19111 2497, USA
Pancreas 37:154-8. 2008....
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancerSteven J Cohen
Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
Cancer Chemother Pharmacol 53:513-8. 2004....
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumorsCrystal S Denlinger
Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Cancer Chemother Pharmacol 65:97-105. 2009..Exploratory analyses of the impact of variability in uridine diphosphate glucuronosyltransferase 1A (UGT1A) genes on irinotecan metabolism and toxicity were conducted...
Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II reportLeonard R Henry
Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111, USA
Ann Surg Oncol 13:214-20. 2006..The incorporation of taxanes into induction strategies for esophageal cancer seems promising, but the optimal schedule remains undefined...
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecanLeslie E Carlini
Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
Clin Cancer Res 11:1226-36. 2005....
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcomeAaron R Sasson
Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Gastrointest Cancer 34:121-8. 2003..Although retrospective,this series suggests an improvement in survival in patients treated with neoadjuvant therapy...
Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communicationNeal J Meropol
Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Clin Oncol 21:2589-96. 2003..To describe and compare the perceptions of cancer patients and their physicians regarding phase I clinical trials...
Identifying cluster subtypes for intentions to have colorectal cancer screening among non-compliant intermediate-risk siblings of individuals with colorectal cancerSharon L Manne
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Health Educ Res 24:897-908. 2009..Results provide an empirical typology for understanding motivations for CRCS among at-risk family members and may lead to the development of more effective interventions to improve screening uptake...
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancerSteven J Cohen
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Clin Oncol 26:3213-21. 2008..We tested the hypothesis that circulating tumor cells (CTCs) could predict clinical outcome in patients with mCRC...
Development of new agents for the treatment of advanced colorectal cancerNancy L Lewis
Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Clin Colorectal Cancer 3:154-64. 2003..This article reviews these recent advances in the systemic treatment of colorectal cancer, including discussion of promising agents in clinical development...
Changing patterns of bone and brain metastases in patients with colorectal cancerMark L Sundermeyer
Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111-2497, USA
Clin Colorectal Cancer 5:108-13. 2005..As survival improves for this patient population, clinicians should be aware of the potential for metastases at previously uncommon sites...
Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancerGary M Freedman
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 67:1389-93. 2007..To determine the safety and efficacy of preoperative hypofractionated radiotherapy using intensity-modulated radiotherapy (IMRT) and an incorporated boost with concurrent capecitabine in patients with locally advanced rectal cancer...
American Society of Clinical Oncology guidance statement: the cost of cancer careNeal J Meropol
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
J Clin Oncol 27:3868-74. 2009..Doing so will require a clear understanding of the factors that drive these costs, as well as potential modifications to the current cancer care system to ensure that all Americans have access to high-quality, cost-effective care...
In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2Klara Berencsi
The Wistar Institute, Philadelphia, PA 19104, USA
J Transl Med 9:33. 2011..To develop such immunotherapeutic strategies for cancer patients, one must identify chemokines and their receptors involved in T-cell migration toward tumor cells...
An Internet method to assess cancer patient information needs and enhance doctor-patient communication: a pilot studyJoanne S Buzaglo
Fox Chase Cancer Center, Divisions of Population Science, Philadelphia, PA, USA
J Cancer Educ 22:233-40. 2007..We therefore developed measures to assess patient communication preferences and established feasibility of an Internet-based intervention to improve communication...
Effects of a decision support intervention on decisional conflict associated with microsatellite instability testingMichael J Hall
Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Cancer Epidemiol Biomarkers Prev 20:249-54. 2011....
Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancerSteven J Cohen
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
Clin Colorectal Cancer 6:125-32. 2006....
The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinomaTracy Klayton
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
J Gastrointest Cancer 43:612-8. 2012..The aim of this study was to determine if a qualitative and quantitative assessment of pre- and post-chemoradiotherapy (CRT) F18-FDG PET scans of esophageal cancer patients could predict for residual disease in esophagectomy specimens...
Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choicesYu Ning Wong
Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111, USA
Oncologist 15:566-76. 2010..The influence of cost on the treatment choices of patients with life-threatening illness, such as cancer, is unknown...
Cost implications of new treatments for advanced colorectal cancerYu Ning Wong
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
Cancer 115:2081-91. 2009..The objective of the current study was to measure the cost implications of treatment with sequential regimens that include chemotherapy and/or monoclonal antibodies...
Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experienceAndre Konski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Semin Oncol 32:S63-7. 2005..Because response to preoperative treatment predicts clinical outcome, the utility of midtreatment PET scans to guide treatment decisions should be further explored in larger clinical studies...
Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancerSharon L Manne
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Clin Oncol 28:1366-72. 2010..To evaluate the impact of a CD-ROM intervention in the education of patients with suspected Lynch syndrome (LS) about microsatellite instability (MSI) and immunohisochemistry (IHC) testing...
Cancer genetic risk assessment and referral patterns in primary careHetal S Vig
Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
Genet Test Mol Biomarkers 13:735-41. 2009..This study was undertaken to describe cancer risk assessment practices among primary care providers (PCPs)...
Targeting signal transduction pathways in colorectal cancer--more than skin deepSteven J Cohen
Division of Medical Science, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111 2497, USA
J Clin Oncol 23:5374-85. 2005....
The impact of misclassification due to survey response fatigue on estimation and identifiability of treatment effectsBrian L Egleston
Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Stat Med 30:3560-72. 2011..The results suggest that measures designed to reduce survey order effects might have unintended consequences. We present a data example that demonstrates the problem of survey order effects...
Knowledge and attitudes about microsatellite instability testing among high-risk individuals diagnosed with colorectal cancerSharon L Manne
Division of Population and Medical Science, Fox Chase Cancer Center, 333 Cottman Avenue, P1100 Philadelphia, PA 19111, USA
Cancer Epidemiol Biomarkers Prev 16:2110-7. 2007..More distressed patients, patients who perceive themselves at higher risk for cancer recurrence, and patients with metastatic disease might be less motivated to have the MSI test...
Telomerase is frequently activated in tumors with microsatellite instabilityInmaculada Ibanez de Caceres
Department of Surgical Oncology, Philadelphia, Pennsylvania, USA
Cancer Biol Ther 3:289-92. 2004..We found similarly frequent activation of telomerase in tumors with and without MMR mutation, suggesting that human tumors with MMR mutation may respond favorably to treatment with telomerase inhibitors...
Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?Nevena Damjanov
Temple University, Fox Chase Temple Cancer Center, Philadelphia, Pennsylvania 19140, USA
Oncology (Williston Park) 18:479-88; discussion 488, 493, 497 passim. 2004....
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexedNancy L Lewis
Division of Medical Science, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
Cancer Chemother Pharmacol 50:257-65. 2002..To determine the maximum tolerated dose (MTD) of raltitrexed when given with irinotecan and to evaluate the pharmacokinetics of these two agents when given in combination...
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinomaSteven J Cohen
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Clin Oncol 21:1301-6. 2003..CONCLUSION: Although treatment with R115777 resulted in partial inhibition of FTase activity in mononuclear cells, it did not exhibit single-agent antitumor activity in patients with previously untreated metastatic pancreatic cancer...
Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancerAhmad L Subhi
Division of Population Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Clin Cancer Res 10:7290-6. 2004..Ornithine decarboxylase is a key enzyme in the regulation of polyamine metabolism. The aim of this study is to analyze MTAP and ornithine decarboxylase (ODC) expression in primary pancreatic tumor specimens...
Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic cultureKlara Berencsi
The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
Cancer Immunol Immunother 56:359-70. 2007....
Proteomic analyses of pancreatic cyst fluidsEileen Ke
From the Divisions of Basic Science, daggerMedical Science, and double daggerPopulation Science, Fox Chase Cancer Center, Philadelphia, PA
Pancreas 38:e33-42. 2009..Proteomic analyses were performed to explore pancreatic cyst fluids to yield effective diagnostic biomarkers...
Correlates of colorectal cancer screening compliance and stage of adoption among siblings of individuals with early onset colorectal cancerSharon Manne
Division of Population Science, Fox Chase Cancer Center, Psycho Oncology Program, Philadelphia, Pennsylvania 19111, USA
Health Psychol 21:3-15. 2002..Physician and family recommendation were also strong correlates. A similar set of factors was associated with stage of adoption of CRC screening...
Drug development in pancreatic cancer: finally, biology begets therapySteven J Cohen
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Gastrointest Cancer 32:91-106. 2002..Currently, there is a renewed optimism that the clinical application of biologic understanding will lead to an improved outcome for patients with pancreatic cancer...
Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancerKalyani Narra
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer Biol Ther 6:1691-9. 2007..The clinical impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP enzymatic activity, in a phase II study of patients with metastatic colorectal cancer...
Circulating tumor cells: evolving evidence and future challengesEfrat Dotan
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
Oncologist 14:1070-82. 2009..This review covers the different techniques available for isolation of CTCs, the clinical utility of CTCs in breast, prostate, and colon cancer, and future directions in this field...
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research studyEfrat Dotan
Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
J Gastrointest Cancer 43:562-9. 2012..This phase II study tested the efficacy and safety of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as first-line treatment for metastatic colorectal cancer patients...
Understanding intention to undergo colonoscopy among intermediate-risk siblings of colorectal cancer patients: a test of a mediational modelSharon Manne
Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Prev Med 36:71-84. 2003....
Multiple behavioral risk factors for colorectal cancer and colorectal cancer screening statusElliot J Coups
Division of Population Science, Fox Chase Cancer Center, 1st Floor, 510 Township Line Road, Cheltenham, PA 19012, USA
Cancer Epidemiol Biomarkers Prev 16:510-6. 2007..In the current study, we examined the prevalence, patterns, and predictors of multiple behavioral risk factors for colorectal cancer according to colorectal cancer screening status (adherent versus not adherent)...
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectantNeal J Meropol
Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
J Clin Oncol 21:1452-8. 2003..To evaluate the safety of recombinant human keratinocyte growth factor (KGF) when administered with fluorouracil (FU) in patients with metastatic colorectal cancer...
Preoperative chemoradiation in the management of adenocarcinoma of the body of the pancreasJuan P Arnoletti
Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Am Surg 68:330-5; discussion 335-6. 2002..In this poor-prognostic subset of patients with pancreatic cancer preoperative chemoradiation followed by an aggressive surgical approach was associated with resectability and long-term survival of a significant minority of patients...
The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integritySalvatore Cortellino
Program in Human Genetics, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Proc Natl Acad Sci U S A 100:15071-6. 2003..MED1 defects (much like MMR defects) may impair cell cycle arrest and apoptosis induced by DNA damage...
Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancerSteven J Cohen
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Clin Cancer Res 8:2116-22. 2002..Evaluation of once-daily dosing of S-1 in malignancies for which fluoropyrimidines have known antitumor activity is warranted...
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab aloneDaniel J Freeman
Department of Oncology Research, Amgen Inc, Thousand Oaks, CA 91320, USA
Clin Colorectal Cancer 7:184-90. 2008..Identifying predictive biomarkers is important to optimally treat patients. This analysis evaluated the association of K-ras, BRAF, and PIK3CA gene mutations with tumor resistance to panitumumab alone...
Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of careJeanne S Mandelblatt
Department of Oncology, Cancer Control Program, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
J Clin Oncol 21:855-63. 2003..There are few data on sequelae of breast cancer treatments in older women. We evaluated posttreatment quality of life and satisfaction in a national population...
Activity of sunitinib in patients with advanced neuroendocrine tumorsMatthew H Kulke
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 26:3403-10. 2008..We evaluated the efficacy of sunitinib in a two-cohort, phase II study of advanced carcinoid and pancreatic neuroendocrine tumor patients...
End points in advanced colon cancer clinical trials: a review and proposalCarmen Allegra
University of Florida, Gainsville, FL, USA
J Clin Oncol 25:3572-5. 2007
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical OncologyLynn M Schuchter
American Society of Clinical Oncology, Alexandria, VA 22314, USA
J Clin Oncol 20:2895-903. 2002
Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trialsKevin P Weinfurt
Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
Cancer 103:140-7. 2005..The authors sought to characterize a special form of numeracy among patients with advanced cancer who were offered participation in Phase I oncology clinical trials...
An exploration of relative health stock in advanced cancer patientsDarrell J Gaskin
Department of Health Policy and Management, Johns Hopkins University, Baltimore, Maryland 21205, USA
Med Decis Making 24:614-24. 2004..Specifically, they estimated the effect of relative health stock on advanced cancer patients' decisions to participate in phase I clinical trials...
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptorLeonard B Saltz
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 22:1201-8. 2004..To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth factor receptor...
Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfactionWenchi Liang
Department of Oncology, Georgetown University Medical Center, Washington, DC 20007, USA
J Clin Oncol 20:1008-16. 2002....
Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trialAnthony F Shields
Department of Medicine, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
Cancer 100:531-7. 2004..The primary endpoint of the study was to determine the objective response rate, and a secondary endpoint was to measure the time to disease progression...
The correlation between patient characteristics and expectations of benefit from Phase I clinical trialsKevin P Weinfurt
Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
Cancer 98:166-75. 2003..The authors examined a range of patient characteristics to determine which factors were associated with greater expectations of benefit from Phase I trials...
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancerFairooz Kabbinavar
Division of Hematology Oncology, University of California Los Angeles, School of Medicine, 90095, USA
J Clin Oncol 21:60-5. 2003....
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661Gini F Fleming
Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
Clin Cancer Res 8:3718-27. 2002..The purpose of this study was to determine the toxicity of escalating doses of trastuzumab when combined with a fixed dose regimen of interleukin (IL)-2...
Global gene expression profiling of circulating tumor cellsDenis A Smirnov
Immunicon Corporation, Huntingdon Valley, Pennsylvania 19006, USA
Cancer Res 65:4993-7. 2005..Genes such as AGR2, S100A14, S100A16, FABP1, and others were found useful for detection of CTCs in peripheral blood of advanced cancer patients...
A phase I study of docetaxel, Cisplatin, 5-Fluorouracil and leucovorinMary F Mulcahy
Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Oncology 68:479-84. 2005..This phase I study was undertaken to determine the maximally tolerated dose and dose-limiting toxicities of a combination of these drugs given in an ambulatory setting using a bolus schedule of 5-FU...
A renewed call for equipoiseNeal J Meropol
J Clin Oncol 25:3392-4. 2007
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancerJ Randolph Hecht
University of California School of Medicine, Los Angeles, CA, USA
Cancer 110:980-8. 2007..The safety and efficacy of the fully human antibody panitumumab was evaluated in patients with metastatic colorectal cancer refractory to available therapies...
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximabShirin Khambata-Ford
Bristol Myers Squibb Co, Princeton, NJ 08543, USA
J Clin Oncol 25:3230-7. 2007..This study was conducted to identify markers that are associated with disease control in patients treated with cetuximab...
The continuum of care: a paradigm for the management of metastatic colorectal cancerRichard M Goldberg
Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Oncologist 12:38-50. 2007....
Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancerBenjamin Movsas
Henry Ford Health System, Radiation Oncology, Detroit, MI 48202, USA
Am J Clin Oncol 29:435-41. 2006..The purpose of this phase II study was to prospectively determine the efficacy of preoperative chemoradiation with a hyperfractionated (Hfx) RT boost to 61.8 Gy in locally advanced rectal cancer...
Patients' decision-making process regarding participation in phase I oncology researchManish Agrawal
Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1156, USA
J Clin Oncol 24:4479-84. 2006..This study assesses the decision-making process of patients enrolling in phase I oncology studies...
Turning point for colorectal cancer clinical trialsNeal J Meropol
J Clin Oncol 24:3322-4. 2006
Gastric Cancer Clinical Practice GuidelinesJaffer Ajani
J Natl Compr Canc Netw 4:350-66. 2006
Esophageal Cancer Clinical Practice GuidelinesJaffer Ajani
J Natl Compr Canc Netw 4:328-47. 2006
Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on targetNeal J Meropol
J Clin Oncol 23:1791-3. 2005
Sequelae of axillary lymph node dissection in older women with stage 1 and 2 breast carcinomaJeanne S Mandelblatt
Department of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC 20007, USA
Cancer 95:2445-54. 2002..There are few data on the long-term sequelae of axillary dissection among older breast carcinoma patients. We describe the impact of axillary dissection in a cohort of older women...
Colorectal cancer: looking forwardNeal J Meropol
Semin Oncol 32:1-2. 2005
